Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

Recruiting now · Phase 2/Phase 3

Conditions studied: Infertility, Infertility (IVF Patients)

In brief

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Key facts

Study ID

NCT07323329

Run by

Beni-Suef University

People needed

165

Starts

2025-10-10

Expected to finish

2026-11-12

Last updated by the study team

2026-01-07

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• At least two of the following three criteria had to be present after maximal stimulation:
• Advanced maternal age (>40 years) or any other risk factor for Poor Ovarian Response (POR).
• ≤3 oocytes with a conventional stimulation protocol).
• An abnormal ovarian reserve test [i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml].

You may not qualify if…

• Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.
• Any pelvic pathology such as hydrosalpinx, uterine anomaly.
• Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia

Where it is running

• Beni-Suef University Hospital — Banī Suwayf, Beni Suweif Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.